Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003
This article was originally published in The Gray Sheet
Executive Summary
Dade Behring's focus on growing its clinical lab diagnostics business while reducing debt, combined with a rising profile on Wall Street and plans to enter the high-volume testing category, are buoying the firm's stock price
You may also be interested in...
Quidel, Digene Among Diagnostic Stocks To Rebound, Excel In 2003
Increased national disease awareness benefited in vitro diagnostics developers in 2003 as new U.S. testing guidelines and the SARS pandemic combined with recovery in the broader economic market to help fuel growth
Staar Warning Letter Presents Challenges For ICL Approval Timeline
Staar Surgical continues to anticipate approval for the Collamer ICL implantable contact lens by April, despite compliance issues raised in a Dec. 22 FDA warning letter
Dade Behring goes public
Diagnostics firm completes pre-packaged Chapter 11 debt restructuring and enters the public market with a new board of directors Oct. 3. The firm expects to complete Nasdaq registration within six months; common equity initially will be traded over-the-counter, with prices listed in the pink sheets. In August, Dade Behring announced a debt-to-equity swap to cover $1.5 bil. in liabilities for the company, then privately held (1"The Gray Sheet" Aug. 5, 2002, p. 16)...